Joint Formulary & PAD

Ethinylestradiol with levonorgestrel - Contraception

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important
Preferred

Preferred brands = Levest, Rigevidon, Maexeni,

 

Status 2

Green
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important

Microgynon 30 ED, TriRegol, Logynon, Logynon ED

 

Status 3

Green (see narrative)
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important

Ovranette / Ambelina / Microgynon 30 - not for new initiations. Existing patients may remain on current brand.

 

Status 4

Non Formulary
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important

Elevin brand is not a cost effective option. 

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Ethinylestradiol with levonorgestrel
Indication :
Contraception
Group Name :
Keywords :
combined hormonal contraceptive, CHC
Brand Names Include :
Levest, Rigevidon, Maexeni, Ovranette, Ambelina, Microgynon 30, Elevin
Important Information :

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
4

Other Indications

Below are listed other indications that Ethinylestradiol with levonorgestrel is used to treat.

  • No records returned.

Committee Recommendations (1)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.